- Home
- HG vs RCKT Comparison
HG vs RCKT Comparison
Compare HG & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | RCKT |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 340.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | HG | RCKT |
|---|---|---|
| Price | $28.09 | $3.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $29.00 | ★ $29.12 |
| AVG Volume (30 Days) | 428.0K | ★ 2.2M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.19 | N/A |
| Revenue | ★ $2,745,461,000.00 | N/A |
| Revenue This Year | $25.41 | N/A |
| Revenue Next Year | $0.82 | N/A |
| P/E Ratio | $6.60 | ★ N/A |
| Revenue Growth | ★ 21.12 | N/A |
| 52 Week Low | $16.80 | $2.19 |
| 52 Week High | $28.11 | $13.50 |
Technical Indicators
Market Signals| Indicator | HG | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 68.42 | 52.07 |
| Support Level | $25.93 | $3.30 |
| Resistance Level | $27.88 | $3.65 |
| Average True Range (ATR) | 0.54 | 0.19 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 99.54 | 66.22 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.